p53 binds to cisplatin-damaged DNA.
We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Here we report using various p53 mutants that two separate domains of p53 protein affect p53 binding to platinated DNA. Mutations within the central core of p53, the domain responsible for sequence-specific DNA binding activity, completely eliminated p53 binding to platinated DNA. Based on competition experiments p53 preferred binding to sequence-specific DNA molecules over platinated DNA molecules. However, p53 binding to platinated DNA molecules was significantly stronger than p53 interactions with DNA molecules lacking damage and a p53 consensus site. Finally, an antibody specific to the C-terminal domain of p53 (pAb421) which activates sequence-specific DNA binding activity inhibited p53 binding to platinated DNA. Taken together, these results suggest that in addition to binding to p53 DNA binding sites, p53 also interacts with cisplatin-damaged DNA molecules.
Wetzel
C C
CC
Wright State University, Department of Biochemistry and Molecular Biology, 3640 Colonel Glenn Hyw, Dayton, OH 45435, USA.
Berberich
S J
SJ
D001483:Base Sequence; D001665:Binding Sites; D002945:Cisplatin / Q000633:toxicity*; D016384:Consensus Sequence; D004247:DNA / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D016158:Genes, p53; D006801:Humans; D008969:Molecular Sequence Data; D011485:Protein Binding; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53; D004247:DNA; D002945:Cisplatin